Aaron Larsen

Aaron Larsen is the Chief Scientific Officer of Crystal NAX, a premier mRNA and LNP CDMO, and a recognized leader in RNA science. With over a decade of experience, he specializes in the design, synthesis, and GMP-scale manufacturing of mRNA and lipid nanoparticle (LNP) technologies. Aaron previously held critical leadership roles at Terrain Biosciences, Resilience, Beam Therapeutics, and Moderna, where he guided novel mRNA therapies and vaccines from initial research through clinical implementation. He holds a PhD in Chemistry from McGill University and completed post-doctoral research at Harvard University, uniquely combining rigorous scientific inquiry with industrial process development to advance the next generation of genetic medicine.